Biophytis Reports 2019 Full Year Results and Provides

Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity

11 September 2026

Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the…

Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

9 September 2026

Biophytis today announces that it has submitted to the Brazilian Health Regulatory Agency (ANVISA) an amendment to the protocol of the phase 2 OBA clinical study in obesity.

Biophytis strengthens its financial position and extends its cash runway into Q1 2027

31 August 2026

Cash position strengthened to €3.0 million Most 2026 share warrants exercised Phase 2 study in obesity to start in Q1 2027 Hong-Kong JV to start operations for preparing Phase 3…

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY

10 August 2026

Biophytis today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the…

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE

3 August 2026

Biophytis provides an update on the rollout of its joint venture in Hong Kong (see details in the “About” section below) and shares its short- and medium-term outlook. Landmark milestones…

Biophytis announces the auditing of its 2025 financial statements and the resumption of trading in its stock

29 July 2026

Biophytis announces the publication of its parent company financial statements for the fiscal year ended December 31, 2025, prepared in accordance with French accounting rules and principles and approved by…

Biophytis Reports 2019 Full Year Results and Provides Operational Update

Other Press Releases

Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity

Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

Biophytis strengthens its financial position and extends its cash runway into Q1 2027

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE

Biophytis announces the auditing of its 2025 financial statements and the resumption of trading in its stock

Addresses

Addresses

Addresses